ViroMissile Advances Phase I Cancer Virus Trial to Higher Dose

ViroMissile, Inc. announced Wednesday that its independent Safety Review Committee has cleared the company's first-in-human Phase I clinical trial of IDOV-2 to advance to a higher dose cohort, following a review of safety data from the initial patient group enrolled in the study.

The San Diego-based cancer immunotherapy company said the first dose cohort of the trial — formally registered as NCT06910657 — has been completed in patients with advanced solid tumors. IDOV-2, previously known as IDOV-Immune, is built on ViroMissile's proprietary IDOV™ platform, which focuses on oncolytic viruses engineered for intravenous delivery rather than direct tumor injection, a technical distinction the company views as central to its approach.

Read more Vima Therapeutics to Present Dystonia Research at 2026 Movement Disorders Congress →

The trial is being conducted at sites in both the United States and Australia, with the Australian operations run through ViroMissile Australia, PTY, LTD, a wholly owned subsidiary. Expansion across two countries suggests the company is seeking to accelerate enrollment and broaden its patient population for the early-stage safety and dosing study.

Oncolytic virus therapies are designed to selectively infect and destroy cancer cells while stimulating an immune response against tumors. The intravenous delivery method targeted by ViroMissile's platform is considered technically challenging but potentially transformative, as it could allow systemic treatment of metastatic disease that is not accessible through localized injection approaches.

Continue reading at GlobeNewswire - Industry News on Financial Services.